Ezetimibe Side Effects, Including Hair Loss: What UK Patients Should Know

Ezetimibe is one of the most commonly prescribed cholesterol-lowering medicines in the UK, often used alongside a statin or as an alternative for patients who cannot tolerate statins. For most people it works quietly in the background, reducing LDL cholesterol without causing much trouble. But a subset of patients notice something unexpected: their hair starts thinning.

If that sounds familiar, you are not alone, and your concern is clinically reasonable. Hair loss (alopecia) is listed in the UK Summary of Product Characteristics (SmPC) for ezetimibe, though the frequency is classified as 'not known' because it comes from post-marketing surveillance rather than controlled clinical trials. That does not mean it is rare, it means it was not captured in sufficient numbers during the original trial programme to assign a precise frequency.

This article covers what the evidence actually shows, how to work out whether ezetimibe is the likely culprit, and what your options are.

How Ezetimibe Works#

Ezetimibe (brand name Ezetrol) reduces LDL cholesterol by blocking the Niemann-Pick C1-Like 1 (NPC1L1) protein in the lining of the small intestine. This protein is responsible for transporting dietary and biliary cholesterol into intestinal cells. By inhibiting it, ezetimibe can lower LDL by around 15-20% when used alone, and more when combined with a statin.

Unlike statins, which work in the liver by blocking the HMG-CoA reductase enzyme, ezetimibe acts exclusively in the gut. This is why its side effect profile looks different. Statins are more likely to cause muscle-related symptoms, while ezetimibe's documented issues are mostly gastrointestinal.

One important and often overlooked consequence of blocking intestinal cholesterol absorption is that ezetimibe may also reduce absorption of fat-soluble vitamins, particularly vitamins D, E, A, and K. These nutrients travel through the same lipid transport pathways in the gut. Vitamin D deficiency is already common in the UK population, and inadequate vitamin E has been associated with hair follicle health. This provides a biologically plausible mechanism by which ezetimibe could contribute to hair thinning, even if the direct causal evidence is not yet robust.

Common Side Effects of Ezetimibe#

The side effects listed in the SmPC and BNF, and confirmed by the NHS medicines information page, fall into a few clear categories.

Common (affects up to 1 in 10 people):

• Abdominal pain and discomfort
• Diarrhoea
• Flatulence
• Fatigue
• Headache

Uncommon (affects up to 1 in 100 people):

• Elevated liver enzymes (more likely when combined with a statin)
• Myalgia (muscle aching)

Rare or very rare:

• Myopathy and rhabdomyolysis (particularly in combination statin therapy)
• Thrombocytopenia (low platelet count)
• Pancreatitis
• Hepatitis
• Cholelithiasis (gallstones, particularly if used with a fibrate)
• Hypersensitivity reactions including anaphylaxis

Not known frequency (from post-marketing reports):

• Alopecia (hair loss)
• Depression

The 'not known' classification is worth understanding properly. It does not mean the side effect is extremely rare. It means the data from spontaneous reporting schemes, including the MHRA Yellow Card system in the UK and equivalent schemes across Europe, shows a signal but the denominator (total number of exposures) makes precise frequency calculation impossible. The European Medicines Agency's periodic safety review for ezetimibe-containing products acknowledges alopecia as a recognised adverse event in this category.

Does Ezetimibe Cause Hair Loss?#

The honest answer is: probably in some patients, but establishing causality is genuinely difficult.

Hair loss has been reported by patients taking ezetimibe since the drug came to market in the early 2000s. These reports, submitted through the Yellow Card scheme and its international equivalents, triggered its inclusion in the 'not known' section of the SmPC. The signal was considered strong enough to warrant listing, but the available evidence does not allow clinicians to say with confidence that ezetimibe caused the hair loss rather than other factors.

There are several mechanisms by which it could plausibly contribute:

Fat-soluble vitamin malabsorption. As discussed above, blocking cholesterol absorption may also reduce uptake of vitamins D and E, both of which play a role in hair follicle cycling.

Cholesterol pathway disruption. Cholesterol is a precursor for steroid hormones including androgens. Altering cholesterol metabolism in the gut could, in theory, affect the hormonal environment at the follicle level, though this remains speculative.

Telogen effluvium. This is a temporary form of hair shedding triggered by physiological stress, illness, rapid weight change, or metabolic shifts. Starting a new medication can sometimes act as a trigger. The hair loss in telogen effluvium typically begins 2-4 months after the triggering event, which is why patients on ezetimibe might not immediately connect the two.

In practice, patients who report hair loss on ezetimibe tend to notice it somewhere between 6 weeks and 6 months after starting the medicine. If you notice thinning outside that window, it is worth considering other causes first.

Is It Ezetimibe, or Something Else?#

This is the most important clinical question, and one that deserves a more structured answer than 'go and see your GP'.

Hair loss is common in the general population and has many causes. Before attributing it to ezetimibe, it is worth systematically considering the following:

Thyroid dysfunction. Both hypothyroidism and hyperthyroidism can cause diffuse hair thinning. It is common in the age group that tends to be prescribed ezetimibe. A TSH blood test will rule this in or out.

Iron deficiency. Low ferritin (stored iron) is one of the most common and underdiagnosed causes of hair shedding in adults, particularly in women. A serum ferritin level below 30 micrograms/litre is associated with telogen effluvium even in the absence of anaemia.

Co-prescribed statin. Many patients take ezetimibe alongside a statin. Statins also list alopecia as a post-marketing adverse effect. If you are on combination therapy and experiencing hair loss, attributing it to either drug alone is very difficult without stopping one at a time, and you should not do this without medical advice.

Androgenetic alopecia. Male and female pattern hair loss is genetic and progresses independently of medication. It often becomes more noticeable in your 40s and 50s, the same demographic likely to be starting ezetimibe. The pattern matters here: androgenetic alopecia follows a predictable recession at the temples or crown, whereas drug-induced hair loss tends to be more diffuse.

Telogen effluvium from another trigger. Significant illness, surgery, crash dieting, childbirth, or a major stressor 2-4 months before the hair loss started could all be responsible.

Recommended blood tests to discuss with your GP or pharmacist:

• TSH (thyroid function)
• Serum ferritin (iron stores, not just haemoglobin)
• Full blood count
• Liver function tests (especially relevant if on combination therapy)
• Vitamin D
• CK (creatine kinase) if muscle symptoms are also present

When to Speak to a Clinician#

You should speak to your GP or pharmacist if:

• Your hair loss began within 6 months of starting ezetimibe and has no other obvious explanation
• You are experiencing other symptoms alongside hair loss (fatigue, muscle pain, jaundice, or rash)
• The hair loss is significant enough to be distressing
• You want to consider a supervised trial of stopping or switching the medication

A structured dechallenge (stopping the suspected drug) followed by rechallenge (restarting it) is the most reliable way to establish whether a drug is causing a side effect, but this should only be done under medical supervision, especially with a cholesterol-lowering medicine where the cardiovascular benefits are significant.

Do not stop ezetimibe abruptly without speaking to your prescriber. For many patients it is prescribed as part of a cardiovascular risk reduction plan, and discontinuing it carries real clinical implications.

For non-urgent concerns, NHS 111 can advise you on whether you need a GP appointment or can wait. If you are experiencing muscle pain, yellowing of the skin, or severe abdominal pain alongside hair loss, seek more urgent attention.

What to Report to the MHRA#

If you suspect ezetimibe is causing your hair loss, you can report it through the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk. This takes about 10-15 minutes and can be done by patients directly. You do not need to have a confirmed diagnosis.

When filling in the report, include:

• The brand and generic name of the medicine
• The dose and how long you have been taking it
• When the hair loss started (relative to starting the medicine)
• Any other medicines you are taking
• Whether the hair loss improved if you stopped or reduced the dose

Patient-reported Yellow Card data is genuinely valuable. The alopecia signal for ezetimibe was strengthened partly by patient submissions. Your report contributes to the evidence base that could lead to clearer prescribing guidance.

Alternatives to Ezetimibe for Cholesterol Management#

If your prescriber agrees that ezetimibe is the likely cause of your hair loss and switching is appropriate, there are several alternatives within the NICE-recommended lipid management pathway.

Statins remain the first-line treatment for most patients. Rosuvastatin, atorvastatin, and pravastatin are all available and have robust cardiovascular outcome data. As noted, some statins also list alopecia as a post-marketing side effect, though the incidence appears low.

PCSK9 inhibitors (evolocumab and alirocumab) are available on the NHS under specific criteria, primarily for familial hypercholesterolaemia or very high cardiovascular risk. NICE technology appraisals TA394 and TA393 set out eligibility. These are injectable medicines given fortnightly or monthly.

Bempedoic acid with ezetimibe (Nustendi) is available under NICE TA694 as an option for patients who cannot tolerate statins. If ezetimibe alone is the problem, this combination is unlikely to help.

Inclisiran (NICE TA733) is a newer injectable option given twice yearly, targeting PCSK9 through a different mechanism. It is licensed for familial and non-familial hypercholesterolaemia.

The right alternative depends on your cardiovascular risk profile, your prior medication history, and whether you are statin-intolerant. NICE guideline NG238 on cardiovascular disease risk assessment and lipid modification sets out the full treatment pathway your GP will follow.

Managing Hair Loss While Staying on Ezetimibe#

For some patients, the cardiovascular benefit of ezetimibe clearly outweighs the hair loss, and switching is not the right decision. In that case, there are practical steps worth considering.

Checking your vitamin D and iron levels is a sensible starting point, since both can be addressed with supplementation if deficient. There is no evidence that supplementing fat-soluble vitamins reverses ezetimibe-associated hair loss, but correcting an underlying deficiency is good practice regardless.

For patients experiencing pattern hair loss alongside medication-related thinning, treatments such as minoxidil (topical or oral) or finasteride (for men) may help maintain density. These are available through Totiva's hair loss service, where a pharmacist can assess which option suits you and whether it fits alongside your current treatment plan.

Telogen effluvium, if that is the mechanism, tends to resolve on its own within 3-6 months once the triggering factor is addressed or stabilises. The hair that has shed usually regrows, though this can take up to a year.

A Note on Combination Therapy#

If you are taking ezetimibe and a statin together and experiencing hair loss, the attribution problem is real. Both drug classes list alopecia as post-marketing adverse effects. The most pragmatic clinical approach is usually to check for other causes first (thyroid, ferritin, vitamin D), then consider stopping one drug at a time under medical supervision if no other explanation is found.

Patients started on ezetimibe as an add-on to statin therapy, which is common in UK practice, should be aware that the combination does not appear to increase hair loss risk additively based on available data, but the data is limited and absence of evidence is not the same as evidence of absence.

If you are unsure where to start or want a pharmacist's view on your specific situation, Totiva offers pharmacist-led consultations that can help you work through your symptoms and options without a long wait. You can start a hair loss consultation online if thinning is your main concern, or speak to us about your broader cholesterol medication query.